KemPharm Inc (KMPH)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

KemPharm Inc (KMPH)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH193165D
  • |
  • Pages: 41
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

KemPharm Inc (KemPharm) is a biopharmaceutical company which focuses on the discovery and development of proprietary new molecular entity prodrugs. Its product pipeline includes KP415, methylphenidate drug for ADHD; and KP511/ER, which is a hydromorphone drug for pain. It is also developing KP303, which is a quetiapine antipsychotic drug to treat multiple central nervous system disorders; and KP606/IR which is a oxycodone drug used for the treatment of pain. KemPharm uses ligand activated therapy, which is a platform technology to produce new molecular entity prodrugs. The company focuses on therapeutic areas such as pain, ADHD and other central nervous system indications. KemPharm is headquartered in Coralville, Iowa, the US.

KemPharm Inc (KMPH)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

KemPharm Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

KemPharm Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

KemPharm Inc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

MonoSol Rx Expands Co-Development Agreement With KemPharm 11

Licensing Agreements 12

KemPharm Enters into Licensing Agreement with Acura Pharma 12

Equity Offering 13

KemPharm to Raise USD20 Million in Public Offering of Shares 13

KemPharm to Raise USD62.7 Million in Public Offering of Shares 14

KemPharm Raises USD56 Million in IPO 15

Debt Offering 16

KemPharm Raises USD86.3 Million in Private Placement of 5.5% Senior Notes Due 2021 16

KemPharm Raises USD10 Million in Private Placement of Notes 18

Asset Transactions 19

Shire Acquires Amphetamine Amino Acid Conjugate Products from KemPharm 19

KemPharm Inc-Key Competitors 20

Key Employees 21

Locations And Subsidiaries 22

Head Office 22

Recent Developments 23

Financial Announcements 23

Mar 09, 2017: KemPharm Reports Fourth Quarter and Year End 2016 Results 23

Nov 09, 2016: KemPharm Reports Third Quarter 2016 Results 24

Aug 10, 2016: KemPharm Reports Second Quarter 2016 Results 25

May 12, 2016: KemPharm Reports First Quarter 2016 Results 27

Mar 10, 2016: KemPharm Reports Q4 and Year End 2015 Results 28

Corporate Communications 30

Jan 07, 2016: KemPharm Added to NASDAQ Biotechnology Index 30

Product News 31

06/06/2016: KemPharm to Present Data from Pharmacokinetic Trial for Investigational Prodrug Benzhydrocodone at the 2016 International Conference on Opioids 31

05/05/2016: Statement Regarding FDA Advisory Committee Meeting on KemPharm's Abuse-Deterrent Product Candidate Apadaz 32

02/19/2016: KemPharm to Present Data From Oral Human Abuse Liability Study for Investigational Drug KP201/APAP at the 2016 AAPM Annual Meeting 33

Product Approvals 34

Oct 25, 2016: KemPharm Files IND for KP201/IR, a Single-Entity Benzhydrocodone HCl Immediate Release Abuse-Deterrent Prodrug for the Treatment of Acute Pain 34

Jul 14, 2016: KemPharm Completes Key Regulatory Meetings with FDA for KP201/IR 35

Mar 24, 2016: KemPharm Receives NDA User Fee Waiver from FDA 36

Mar 14, 2016: KemPharm Announces FDA Advisory Committee Meeting For Lead Abuse-Deterrent Drug Candidate KP201/APAP 37

Feb 10, 2016: FDA Grants Priority Review to KemPharm for KP201/APAP NDA 38

Other Significant Developments 39

Sep 15, 2016: KemPharm Provides Corporate and Clinical Update 39

Appendix 41

Methodology 41

About GlobalData 41

Contact Us 41

Disclaimer 41

List of Figures

KemPharm Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

KemPharm Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

List of Tables

KemPharm Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1

KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

KemPharm Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

KemPharm Inc, Deals By Therapy Area, 2011 to YTD 2017 9

KemPharm Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

MonoSol Rx Expands Co-Development Agreement With KemPharm 11

KemPharm Enters into Licensing Agreement with Acura Pharma 12

KemPharm to Raise USD20 Million in Public Offering of Shares 13

KemPharm to Raise USD62.7 Million in Public Offering of Shares 14

KemPharm Raises USD56 Million in IPO 15

KemPharm Raises USD86.3 Million in Private Placement of 5.5% Senior Notes Due 2021 16

KemPharm Raises USD10 Million in Private Placement of Notes 18

Shire Acquires Amphetamine Amino Acid Conjugate Products from KemPharm 19

KemPharm Inc, Key Competitors 20

KemPharm Inc, Key Employees 21

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

KemPharm Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16065
Site License
USD 500 INR 32130
Corporate User License
USD 750 INR 48195

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com